GRAIL, LLC (GRAL)vsMerck & Company Inc (MRK)
GRAL
GRAIL, LLC
$61.64
-2.03%
HEALTHCARE · Cap: $2.69B
MRK
Merck & Company Inc
$111.38
-0.82%
HEALTHCARE · Cap: $277.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 44588% more annual revenue ($65.77B vs $147.17M). MRK leads profitability with a 13.6% profit margin vs -277.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).
GRAL
Hold36
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GRAL.
Margin of Safety
-14.9%
Fair Value
$97.76
Current Price
$111.38
$13.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -16.1% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Price/Book. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GRAL profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
GRAL is growing revenue faster at 14.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a leading biotechnology innovator specializing in groundbreaking blood tests for early cancer detection, leveraging its proprietary genomic technologies to transform the multi-cancer early detection (MCED) landscape. By providing individuals with crucial insights for proactive health management, GRAIL is committed to advancing precision medicine and significantly improving patient outcomes. The company's pioneering efforts aim to fill critical gaps in existing cancer screening and diagnostics, solidifying its position as a vital entity in the evolving oncology sector.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?